Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway

Table 1 Metabolic and physiological parameters in mice

	NC (n = 11)	DB (n = 7)	EM/DB (n = 7)
FBG (mmol/L)	4.98 ± 0.82	33.51 ± 2.961	19.26 ± 3.122
HbA1c (%)	4.47 ± 0.14	9.15 ± 1.161	6.86 ± 0.812
INS (mU/L)	82.88 ± 17.85	325.80 ± 47.301	176.30 ± 30.892
HOMO-IR	19.22 ± 5.76	472.60 ± 83.221	190.50 ± 113.502
TC (mmol/L)	2.57 ± 0.30	4.27 ± 0.181	4.27 ± 0.271
HW/BW ( 10-3)	5.21 ± 0.17	5.77 ± 0.121	5.78 ± 0.091
SABP (mmHg)	122.70 ± 2.37	122.90 ± 3.71	123.60 ± 5.03

¹P 0.05 vs normal control mice.

²P 0.05 vs db/db mice.

Data are presented as the mean ± SD. NC: Normal control mice; DB: Db/db mice; EM: Empagliflozin; FBG: Fasting blood glucose; INS: Serum insulin; HW/BW: Ratio of heart weight to body weight; SABP: Systolic arterial blood pressure.